Description

Temomedak (Temozolomide) Capsules 250 mg. №5 Vial

Ingredients:

Each capsule contains 250 mg of Temozolomide.

Dosage:

The usual adult dose is 150-200 mg/m² once daily for 5 consecutive days per 28-day treatment cycle.

Indications:

Temomedak is indicated for the treatment of certain types of brain tumors, specifically glioblastoma multiforme and anaplastic astrocytoma.

Contraindications:

Do not use Temomedak if you are allergic to Temozolomide or any of the ingredients in the product.

Directions:

Take Temomedak capsules orally on an empty stomach, at least 1 hour before or 2 hours after a meal. Follow the dosage instructions provided by your healthcare provider.

Scientific Evidence:

Temozolomide, the active ingredient in Temomedak, is an oral alkylating agent that works by slowing or stopping the growth of cancer cells. Studies have shown that Temozolomide is effective in the treatment of malignant gliomas, including glioblastoma multiforme, both as a monotherapy and in combination with radiation therapy.

Additional Information:

It is important to discuss the potential side effects and risks of Temomedak with your healthcare provider before starting treatment. Common side effects may include nausea, vomiting, fatigue, and low blood cell counts. Regular blood tests are necessary to monitor for any adverse effects on blood cells.

Research has also indicated that Temozolomide may have a role in the treatment of other types of cancers, such as metastatic melanoma and certain types of brain metastases. Clinical trials are ongoing to explore the full potential of Temozolomide in various cancer types.